ALC.SW Alcon Inc. (SIX) pre-market: CHF64.68, most active ahead of Feb earnings
ALC.SW stock is trading at CHF64.68 in the pre-market as volume tops 1,360,937 shares and the name ranks among the most active on the SIX in Switzerland. Investors are focused on the 2026-02-24 earnings date and short-term momentum after a modest intraday move of -0.34 CHF (-0.52%). The mix of a high price-to-earnings multiple (PE 38.50) and stable free cash flow keeps Alcon in market crosshairs. We summarise valuation, technicals, Meyka AI forecasts and key risks for traders watching today
ALC.SW stock market snapshot and drivers
Pre-market trading shows ALC.SW stock at CHF64.68, down 0.34 CHF (-0.52%), with a day range CHF63.84–65.68 and year range CHF57.68–87.00. Volume is 1,360,937 versus average volume 1,164,541, giving relative volume 1.17 and confirming the most-active status on SIX.
The immediate drivers are positioning ahead of the February 24 earnings release, solid surgical and vision-care demand, and broader Healthcare sector strength. Traders should watch order flow and the bid-ask spread in pre-market hours for intraday execution clues.
ALC.SW stock fundamentals and valuation
Alcon reports EPS 1.68 and a PE of 38.50, valuing growth prospects above the Swiss Healthcare sector average. Key ratios show price-to-sales 3.98, price-to-book 1.83, and free cash flow yield 3.92%, suggesting moderate premium but healthy cash conversion.
Balance-sheet metrics support the valuation: current ratio 2.12, debt-to-equity 0.24, and interest coverage 7.25. Dividend yield is modest at 0.43% and payout ratio 15.34%, which limits income appeal but preserves cash for reinvestment.
ALC.SW stock technicals and trading signals
Technicals show a neutral to constructive trading setup: RSI 58.62, MACD histogram 0.03, and the 50-day average CHF63.19 vs 200-day CHF66.96. Bollinger Bands middle is CHF63.72 and ATR is 1.10 CHF, indicating moderate volatility.
Short-term momentum favors buyers, but ADX 14.16 signals no strong trend. Active traders should monitor the CHF63.20–66.00 band for breakout or rejection.
Meyka AI rates ALC.SW with a score out of 100 and analyst view
Meyka AI rates ALC.SW with a score out of 100: 71.34 | Grade B+ | Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The platform flags a solid cash-flow profile and manageable leverage as strengths, and a relatively high PE and inventory cycle as cautionary items.
Independent rating from 2026-01-22 lists a company rating B (Neutral) with mixed metric recommendations: DCF Buy but PE and DE flagged as weaker. These grades are not guaranteed and we are not financial advisors.
ALC.SW earnings, catalysts and sector context
Earnings are set for 2026-02-24; surgical segment results and margin commentary will be key catalysts. Alcon’s Surgical and Vision Care segments expose it to growth in cataract procedures and daily disposable contact lens demand, both important for revenue mix.
Within Switzerland’s Healthcare sector—where average PE is 34.40—Alcon’s premium PE and heavier exposure to devices mean earnings surprise risk can drive big moves. Watch guidance on procedure volumes, product launches, and pricing trends.
ALC.SW stock forecast, price targets and risks
Meyka AI’s forecast model projects a monthly price of CHF69.13 and a yearly price of CHF62.59. That implies a near-term upside of +6.88% to the monthly projection and an implied 12-month downside of -3.23% versus the current CHF64.68. Forecasts are model-based projections and not guarantees.
Primary risks include a long cash conversion cycle (days inventory 194.07), dependence on elective procedure volumes, and margin pressure from product mix shifts. Opportunities include proprietary IOLs, refractive lasers, and contact-lens growth in emerging markets.
Final Thoughts
ALC.SW stock trades as one of the most active SIX names in this pre-market session at CHF64.68, driven by volume and an upcoming 2026-02-24 earnings release. The company’s fundamentals show healthy cash flow and low leverage, but a premium PE 38.50 and a long inventory cycle increase sensitivity to demand swings. Meyka AI’s forecast model projects a monthly target of CHF69.13 (implied +6.88% upside) and a yearly target of CHF62.59 (implied -3.23% downside). Traders should weigh short-term momentum and the most-active status against event risk from the earnings call. For investors, the B+ Meyka grade reflects a BUY suggestion based on relative sector performance and cash-flow strength, while reminding readers that grades are model outputs and not personal investment advice. See full market data and the Alcon company page on Meyka for live updates and execution details
FAQs
What is the current price and volume for ALC.SW stock in pre-market?
ALC.SW stock is at CHF64.68 in the pre-market with volume 1,360,937 shares versus average 1,164,541, confirming above-average activity on the SIX.
How does Meyka AI view ALC.SW stock valuation?
Meyka AI notes Alcon’s PE 38.50, price-to-book 1.83, and free cash flow yield 3.92%, assigning a B+ grade and BUY suggestion while warning the valuation is a modest premium to the sector.
What are the near-term forecasts and price targets for ALC.SW stock?
Meyka AI’s forecast model projects CHF69.13 monthly (implied +6.88%) and CHF62.59 yearly (implied -3.23%) versus the current CHF64.68. Forecasts are model-based projections and not guarantees.
When is Alcon’s next earnings report and why does it matter for ALC.SW stock?
Alcon reports on 2026-02-24; results on surgical volumes, IOL demand and margin guidance can trigger large moves given the stock’s premium valuation and current high trading activity.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
